Indivior FY2026 EPS Estimate Boosted by Northland Securities

Indivior PLC (NASDAQ:INDV) – Northland Securities raised their FY2026 earnings estimates for shares of Indivior in a research note issued on Tuesday, January 20th. Northland Securities analyst C. Byrnes now expects that the company will post earnings of $2.65 per share for the year, up from their previous forecast of $2.25. The consensus estimate for Indivior’s current full-year earnings is $1.22 per share. Northland Securities also issued estimates for Indivior’s Q4 2026 earnings at $0.71 EPS.

A number of other brokerages also recently issued reports on INDV. Morgan Stanley reiterated an “overweight” rating and set a $36.00 price target on shares of Indivior in a research report on Wednesday, December 3rd. HC Wainwright upped their target price on Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Zacks Research lowered Indivior from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 13th. Piper Sandler reissued an “overweight” rating and issued a $41.00 price target (up previously from $27.00) on shares of Indivior in a research note on Friday, October 31st. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Indivior in a research report on Friday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, Indivior has a consensus rating of “Moderate Buy” and an average price target of $36.00.

Indivior Stock Up 1.7%

INDV stock opened at $33.54 on Thursday. Indivior has a 52-week low of $7.62 and a 52-week high of $38.00. The firm has a market cap of $4.19 billion, a P/E ratio of 36.46 and a beta of 0.75. The company’s 50-day simple moving average is $34.54 and its 200-day simple moving average is $27.04.

Indivior (NASDAQ:INDV) last released its quarterly earnings results on Thursday, October 30th. The company reported $0.72 EPS for the quarter, beating the consensus estimate of $0.38 by $0.34. Indivior had a net margin of 9.83% and a negative return on equity of 90.79%. The company had revenue of $314.00 million for the quarter, compared to analyst estimates of $257.66 million.

Insider Transactions at Indivior

In other news, Director Barbara Ryan acquired 775 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were bought at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the acquisition, the director owned 1,963 shares of the company’s stock, valued at approximately $69,470.57. This trade represents a 65.24% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Daniel A. Ninivaggi bought 775 shares of the stock in a transaction on Monday, January 5th. The shares were acquired at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the purchase, the director owned 16,923 shares in the company, valued at $598,904.97. The trade was a 4.80% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired 4,871 shares of company stock worth $172,385 in the last quarter.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Indivior by 16.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company’s stock valued at $71,000 after purchasing an additional 666 shares during the last quarter. Blue Trust Inc. boosted its stake in Indivior by 17.8% during the fourth quarter. Blue Trust Inc. now owns 4,859 shares of the company’s stock worth $176,000 after buying an additional 733 shares during the last quarter. Harbor Capital Advisors Inc. grew its holdings in Indivior by 309.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock valued at $37,000 after buying an additional 781 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Indivior by 544.6% in the 4th quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock worth $43,000 after acquiring an additional 1,013 shares during the last quarter. Finally, CWM LLC purchased a new position in shares of Indivior during the 3rd quarter worth $25,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.